-
Views
-
Cite
Cite
Y. Teraki, T. Fukuda, Pemphigoid nodularis associated with psoriatic erythroderma: successful treatment with suplatast tosilate, British Journal of Dermatology, Volume 158, Issue 2, 1 February 2008, Pages 424–426, https://doi.org/10.1111/j.1365-2133.2007.08333.x
Close - Share Icon Share
Extract
Conflicts of interest: none declared.
Sir, Bullous pemphigoid (BP) is a chronic autoimmune blistering skin disease characterized by the presence of immunoglobulin (Ig) G autoantibodies specific for the hemidesmosomal BP antigens.1 Skin lesions of BP are typically pruritic tense blisters, that are sometimes followed by urticarial plaques. BP may also present with several distinct clinical presentations including nodular variants.2, 3 Pemphigoid nodularis (PN) is a rare clinical variant of BP that is characterized by the presence of clinical features that overlap with both nodular prurigo‐like lesions and pemphigoid blisters. Although the histopathology of nodular lesions shows typical features of nodular prurigo, the findings on direct immunofluorescence are identical with those of BP.
On the other hand, BP has often been described in association with psoriasis.4, 5 However, the relationship between BP and psoriasis is unclear. We report a case of PN that occurred after the patient had been diagnosed as having psoriatic erythroderma, and the pemphigoid disease activity was strongly correlated with serum IgE levels. In this case, treatment with suplatast tosilate, a selective Th2 cytokine inhibitor, successfully improved the pemphigoid lesions.
